Literature DB >> 22265157

HMGB1 is overexpressed in tumor cells and promotes activity of regulatory T cells in patients with head and neck cancer.

Clarissa A Wild1, Sven Brandau, Ramin Lotfi, Stefan Mattheis, Xiang Gu, Stephan Lang, Christoph Bergmann.   

Abstract

HMGB1 has gained a prominent role in cancer development and is implicated in tumor escape phenomena. To date, only few data are available on effects of HMGB1 on regulatory T cells (Treg) in cancer patients. This study evaluates the prevalence of HMGB1 and its effects on Treg in patients with head and neck squamous cell carcinoma (HNSCC). Sixty-seven patients with HNSCC and seventeen healthy donors were included in this study. Tumor tissues of patients were analyzed for expression of HMGB1 employing immunofluorescence and qRT-PCR. HMGB1 serum levels were assessed using ELISA. Tumor-infiltration and Treg from peripheral blood were phenotyped with flow cytometry and immunofluorescence microscopy. Migration and suppressive function of Treg upon HMGB1 stimulation was analyzed in chemotaxis assays and CFSE assays. HMGB1 is overexpressed in tumor cells of HNSCC, and serum levels are significantly elevated. Tumor-infiltrating Treg express HMGB1-recognizing receptors, TLR4 and RAGE. HMGB1 is a chemoattractant for Treg and promotes their suppressive function. Our data provide new aspects how the HMGB1 tumor-derived danger signal augments function of Treg in patients with HNSCC.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22265157     DOI: 10.1016/j.oraloncology.2011.12.009

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  33 in total

1.  [Immunotherapy of head and neck cancer. Current developments].

Authors:  P J Schuler; T K Hoffmann; T C Gauler; C Bergmann; S Brandau; S Lang
Journal:  HNO       Date:  2013-07       Impact factor: 1.284

2.  Expression of aldehyde dehydrogenase family 1 member A1 and high mobility group box 1 in oropharyngeal squamous cell carcinoma in association with survival time.

Authors:  Xu Qian; Annekatrin Coordes; Andreas M Kaufmann; Andreas E Albers
Journal:  Oncol Lett       Date:  2016-09-07       Impact factor: 2.967

3.  Deletion of CD24 impairs development of heat shock protein gp96-driven autoimmune disease through expansion of myeloid-derived suppressor cells.

Authors:  Jessica E Thaxton; Bei Liu; Pan Zheng; Yang Liu; Zihai Li
Journal:  J Immunol       Date:  2014-05-07       Impact factor: 5.422

4.  Life after death: targeting high mobility group box 1 in emergent cancer therapies.

Authors:  Z Sheng Guo; Zuqiang Liu; David L Bartlett; Daolin Tang; Michael T Lotze
Journal:  Am J Cancer Res       Date:  2013-01-18       Impact factor: 6.166

Review 5.  Certainty of S100 from Physiology to Pathology.

Authors:  Puneeth Horatti Kuberappa; Bhavana Shivanand Bagalad; Anuradha Ananthaneni; Md Asif Kiresur; Guduru Vijay Srinivas
Journal:  J Clin Diagn Res       Date:  2016-06-01

Review 6.  HMGB1 in health and disease.

Authors:  Rui Kang; Ruochan Chen; Qiuhong Zhang; Wen Hou; Sha Wu; Lizhi Cao; Jin Huang; Yan Yu; Xue-Gong Fan; Zhengwen Yan; Xiaofang Sun; Haichao Wang; Qingde Wang; Allan Tsung; Timothy R Billiar; Herbert J Zeh; Michael T Lotze; Daolin Tang
Journal:  Mol Aspects Med       Date:  2014-07-08

Review 7.  Pivotal role of high-mobility group box 1 (HMGB1) signaling pathways in glioma development and progression.

Authors:  Efthalia Angelopoulou; Christina Piperi; Christos Adamopoulos; Athanasios G Papavassiliou
Journal:  J Mol Med (Berl)       Date:  2016-06-04       Impact factor: 4.599

8.  [Regulatory T cells and NK cells in cancer patients].

Authors:  C Bergmann
Journal:  HNO       Date:  2014-06       Impact factor: 1.284

Review 9.  Until Death Do Us Part: Necrosis and Oxidation Promote the Tumor Microenvironment.

Authors:  Ramin Lotfi; Christof Kaltenmeier; Michael T Lotze; Christoph Bergmann
Journal:  Transfus Med Hemother       Date:  2016-03-08       Impact factor: 3.747

Review 10.  Immunogenic tumor cell death induced by chemoradiotherapy: molecular mechanisms and a clinical translation.

Authors:  K Kono; K Mimura; R Kiessling
Journal:  Cell Death Dis       Date:  2013-06-20       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.